GSK R&D President Patrick Vallance On Increasing R&D Productivity: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
An R&D model aimed at bringing the pressure and promise of startups to life within GlaxoSmithKline PLC continues to be tweaked, according to Patrick Vallance, president of pharmaceuticals R&D. He sat down with PharmAsia News during a recent visit to Singapore to give an overview of the company’s strategy.
You may also be interested in...
GSK’s Breo Ellipta Gets “Snowquestered” As FDA Delays Advisory Cmte
FDA missed its deadline to post the advisory committee briefing materials then postponed the meeting as a winter storm headed towards Washington.
GSK Is Getting Ready For A Return To The ’90s
Though it has left behind the “industrialized” R&D approaches from the 1990s, Glaxo thinks its R&D revolution has produced strong growth that will get it back into major markets and maintain an output of three to five significant drug approvals per year. With that progress in sight, the firm is ready to transform its manufacturing and commercial model in the same way it recreated R&D.
Glaxo Confident In Output From Its Revamped R&D Engine
Britain’s biggest drug maker updated the investment community on its pipeline prospects Dec. 3, outlining a timescale of three pipeline “waves” that will include pivotal clinical trial results on up to 14 medicines in the next two years.